On March 26, 2025, Juncell Therapeutics announced that the abstract of the mechanism study on the innovative preconditioning regimen for its tumor-infiltrating lymphocyte (TIL) therapy has been published on the official website of the American Association for Cancer Research (AACR) 2025 Annual Meeting.

This study indicated that hydroxychloroquine (HCQ) could significantly increase the tumor-killing effects via elevating the membrane MHC-I protein levels of tumor cells without affecting TILs'proliferation. In addition, its effect on surface PD-L1 expression was not significant compared with IFN-γ. These results provide preclinical evidence for HCQ pretreatment of the adoptive cell therapy of TILs in clinical trials.

Details of the poster presentation are below:

Abstract Number: 5827
Abstract Title: Hydroxychloroquine increases the tumor killing efficiency via elevating the membrane MHC-I protein levels of tumor cells
Session Title: Immunomodulatory Agents and Interventions
Location: Poster Section 29
Poster Board Number: 3
Poster Presentation Time: 2:00 PM - 5:00 PM CST, April 29, 2025